Sanofi buys ex-US rights to Ful­crum's Phase 3 rare neu­ro­mus­cu­lar drug

Sanofi will pay $80 mil­lion up­front to snag the ex-US li­cense to Ful­crum Ther­a­peu­tics’ rare neu­ro­mus­cu­lar dis­ease treat­ment can­di­date, which will have Phase 3 da­ta …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER